Meeting Presentations Available
Membership
ISCTM Meeting Archives
ISCTM Meeting Archives
Videos and Presentations beginning with the 9th Annual Scientific Meeting are public access. Viewing prior materials will require logging into the ISCTM website.
Membership
Join/Renew, update your profile, view membership categories/dues, access member directory, member benefits, Sustaining Corporation members.
Working Groups
Overview of current and completed working groups, links to ISCTM guidance responses, information on joining and/or starting an ISCTM Working Group.
Publications
Search for ISCTM related publications, access ISCTM Innovations in Clinical Neuroscience supplements.
Upcoming Calendar
12 December 2019 – Deadline Executive Committee Nominations
7 January 2020 – Early Bird Discount expires 16th Annual Scientific Meeting
19-21 February 2020 – 16th Annual Scientific Meeting
The Grand Hyatt, Washington DC
Mark your calendars
22-23 September – 2020 Autumn Conference
The Boston Park Plaza, Boston, MA
(Poster submission deadline, Thursday 9 July)
17-19 February – 2021 – 17th Annual Scientific Meeting
The Grand Hyatt, Washington DC
NEW ISCTM Working Group
Chairs: Walter Dunn, MD, PhD; Zimri Yaseen, MD
Recent years have seen a steady increase in the new applications of somatic therapies that target symptom change in interaction with psychotherapeutic interventions. Examples range from use of repetitive transcranial magnetic stimulation combined with symptom provocation for obsessive compulsive disorder, to intranasal oxytocin combined with social cognition training for young people with early psychosis, to use of MDMA to enhance non-directive psychotherapy grounded in psychodynamic principles to treat adults with post-traumatic stress disorder.
In clinical trials settings such integrated interventions pose a variety of technical and conceptual problems. These issues include:
• defining psychotherapy
• characterization of the psychotherapy component of an integrated intervention
• addressing potentially treatment-intrinsic functional unblinding (e.g., psychedelic psychotherapy)
• accounting for effects of integrated intervention components (e.g., 2×2 trial designs)
• accounting for psychotherapist effects
• evaluating distinctive or novel endpoints (e.g., extinction learning, intra-therapeutic process outcomes such as working alliance)
• distinctive needs in, limits on, and characteristics of regulation of medication-psychotherapy combinations
We are convening a Working Group to gather those who are currently investigating such integrated intervention approaches, to engage trialists who would like to investigate such approaches, and bring to the table those who are cautious or concerned about such approaches or their regulation, and begin an effort to better understand how integrated interventions can best be studied to support understanding of mechanisms, demonstrations of efficacy, and regulatory decision-making.
Inaugural Meeting: 16th Annual Scientific Meeting Working Group Session, 19-21 February, Washington DC
Contact the secretariat with your interest: isctm@isctm.org